ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
SPDR S&P Telecom ETF

SPDR S&P Telecom ETF (XTL)

107.70
2.78
(2.65%)
Al cierre: 21 Noviembre 3:00PM
107.70
0.00
( 0.00% )
Fuera de horario: 6:38PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
107.70
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
9,067
105.73 Rango del Día 107.88
67.08 Rango de 52 semanas 110.38
Capitalización de Mercado [m]
Precio Anterior
104.9218
Precio de Apertura
105.84
Última hora de negociación
18:38:27
Volumen financiero
US$ 973,639
Precio Promedio Ponderado
107.3827
Volumen promedio (3 m)
12,829
Acciones en circulación
775,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2,456.26
Beneficio por acción (BPA)
-0.04
turnover
671k
Beneficio neto
-34k

Acerca de SPDR S&P Telecom ETF

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the telecommunications segment of a U. In seeking to track the performance of the S&P Telecom Select Industry Index (the index), the fund e... The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the telecommunications segment of a U. In seeking to track the performance of the S&P Telecom Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the telecommunications segment of the S&P Total Market Index (S&P TMI). Mostrar más

Sector
Mgmt Invt Offices, Open-end
Industria
Mgmt Invt Offices, Open-end
Sitio web
Sede
Boston, Massachusetts, USA
Fundado
-
SPDR S&P Telecom ETF is listed in the Mgmt Invt Offices, Open-end sector of the American Stock Exchange with ticker XTL. The last closing price for SPDR S&P Telecom ETF was US$104.92. Over the last year, SPDR S&P Telecom ETF shares have traded in a share price range of US$ 67.08 to US$ 110.38.

SPDR S&P Telecom ETF currently has 775,000 shares in issue. The market capitalisation of SPDR S&P Telecom ETF is US$81.31 million. SPDR S&P Telecom ETF has a price to earnings ratio (PE ratio) of -2456.26.

XTL Últimas noticias

XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced an update to its December 8, 2008 press release regarding...

XTLbio Announces Grant of hMAb Patent

XTLbio Announces Grant of Human Monoclonal Antibody Patent Patent Covers Antibodies Directed Against Hepatitis B Virus Surface Antigen Rehovot, Israel 26 January 2004 - XTL Biopharmaceuticals...

XTLbio appoints Stockbroker and Financial Adviser

XTLbio appoints Stockbroker and Financial Adviser Rehovot, 20 January 2004 - The Board of XTL Biopharmaceuticals Ltd ("XTLbio" or the "Company") is pleased to announce the appointment of Code...

XTLbio announces appointment of Non-Executive Director

XTLbio announces appointment of Non-Executive Director Rehovot, 12 January 2004 - XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to announce the appointment of Peter Stalker, III, as a...

Business Update

RNS Number:2908T XTL Biopharmaceuticals Limited 16 December 2003 XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today...

XTLbio R&D and Business Development Update

XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today announces an update on recent clinical progress and corporate developments...

XTLbio Highlights Presence at The Liver Meeting

XTLbio Highlights Presence at The Liver Meeting HepeX Programs at 54th Annual AASLD include Poster Presentations, Oral Presentation and Exhibitors Booth Rehovot, Israel, 28 October 2003: XTL...

Directorate Change

XTLbio announces appointment of Non-Executive Director Rehovot, Israel, 20 October 2003: XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to announce the appointment of Dr. Hadar Ron as a...

Holding(s) in Company

NOTIFICATION OF MAJOR INTERESTS IN SHARES 1) Name of company XTL Biopharmaceuticals Limited 2) Name of shareholder having a major interest Perpetual Income & Growth Investment Trust plc 3) Please...

XTLbio ACQUIRES RIGHTS FROM STANFORD UNIVERSITY

XTLbio ACQUIRES BROAD RIGHTS FROM STANFORD UNIVERSITY TO ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS (HCV) Exclusive license enhances XTLbio's HepeX-C program in clinical development Rehovot...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.18-0.166852057842107.88107.88103.0314458104.99538461SP
45.35.17578125102.4110.38100.8716040105.65536274SP
1214.5315.59514865393.17110.3891.3812829101.79193944SP
2632.1342.516871774575.57110.3872.41531050793.90818121SP
5237.3453.069926094470.36110.3867.08745088.6614225SP
1567.377.34575899532100.33110.3864.09707284.16005867SP
26039.2257.272196261768.48110.3848.47923485.60141395SP

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VRPXVirpax Pharmaceuticals Inc
US$ 1.14
(93.32%)
12.64M
MTEMMolecular Templates Inc
US$ 0.5818
(53.11%)
12.72M
EYENEyenovia Inc
US$ 0.144
(37.01%)
12.91M
SKKSKK Holdings Limited
US$ 1.48
(34.55%)
6.61M
BENFBeneficient
US$ 1.11
(26.14%)
1.36M
CETXCemtrex Inc
US$ 0.1499
(-23.79%)
4.25M
VINOGaucho Group Holdings Inc
US$ 1.17
(-15.83%)
16.05k
KSCPKnightscope Inc
US$ 15.40
(-15.80%)
52.24k
BTAIBioXcel Therapeutics Inc
US$ 0.49
(-14.13%)
84.7k
LGTYLogility Supply Chain Solutions Inc
US$ 9.66
(-13.75%)
26.45k
ELABElevai Labs Inc
US$ 0.02
(-0.99%)
17.19M
EYENEyenovia Inc
US$ 0.144
(37.01%)
12.91M
MTEMMolecular Templates Inc
US$ 0.5818
(53.11%)
12.72M
VRPXVirpax Pharmaceuticals Inc
US$ 1.14
(93.32%)
12.64M
CDTConduit Pharmaceuticals Inc
US$ 0.105
(-2.69%)
10.33M
The Night Stalker The Night Stalker 3 minutos hace
nice
KULR
SavetheOTC SavetheOTC 3 minutos hace
I wouldn't call it a nervous breakdown, but yeah, there's no way an actual breakthrough AI technolgy for mental health agreed to sell 100% for 10 million shares of NFTM.
NFTM
SavetheOTC SavetheOTC 3 minutos hace
I wouldn't call it a nervous breakdown, but yeah, there's no way an actual breakthrough AI technolgy for mental health agreed to sell 100% for 10 million shares of NFTM.
NFTM
jimr1717 jimr1717 4 minutos hace
Have the Korean Hedge Funds Covered their 6 trillion share short yet? Tia
IFUS
maxine523 maxine523 4 minutos hace
Well this is fun!
GeorgeTheStub GeorgeTheStub 4 minutos hace
$1.55 up now, have a good evening, GLTY tomorrow!
misterfishman misterfishman 5 minutos hace
We just need some news to stabilize this drifting down.
IGPK
Zardiw Zardiw 5 minutos hace
Damn.......Their real scariest weapon is threatening guys with harm to their family members.......that's how they control people.......

Z
jimr1717 jimr1717 5 minutos hace
Just a heads up, 🏆️ How did $102.000 in inventory disappear with no record? The last report filed shows that existing inventory fell from $120,000 of feed stock to $18,000 in a year ... even though there were only $20,000 of sales in the entire year. So, $102,000 of inventory disappeared wit
IFUS
hookrider hookrider 5 minutos hace
zab: Always!!!
ah86 ah86 6 minutos hace
Yes, you're wrong on some fronts. This is an open label trial. You can see failure from across the Atlantic. No company as is the case with this one, can have 'bad data' and put it in the fridge.
Patience is key here. Just over 3 bucks. You may walk away with some $$ if you sell now, though
MRKR
RIGATONI RIGATONI 6 minutos hace
100% cleaning house! ~Rig
Judah137 Judah137 6 minutos hace
Is it connected though? This guy seems to have the best investigational skills on the planet:

https://stocktwits.com/MDEUS33/message/585393569

NEOM
HyGro HyGro 6 minutos hace
Let's see how MHRA responds. FDA already reviewed NWBO's P3 and clearly did not encourage NWBO to apply for U.S. approval.

Once again show's AI's flaws as it has repeated errors in their statement.
NWBO
SkeBallLarry SkeBallLarry 6 minutos hace
Comcast Drops Bombshell on MSNBC – Greenlights $7 Billion Spinoff of Cable Channels >

https://pjnewsletter.com/msnbc-comcast-nbcuniversal-cable/
The Night Stalker The Night Stalker 7 minutos hace
nice
CAVR
12yearplan 12yearplan 7 minutos hace
[yt]S3WfSftHQnI[/yt]
noradio noradio 8 minutos hace
This company made 11 million in profit in 2023, am I reading the financials correctly?
CNRC
SavetheOTC SavetheOTC 8 minutos hace
Well, the flip side to that coin is all they've gained is shares, so if they can't create a demand for the stock, this will all be a huge waste of their time.
NFTM
facts_matter14 facts_matter14 8 minutos hace
I’m not hearing about “basket trades” anymore. Total silence. I wonder why………

POSRMX sucks!






.
SRMX
HyGro HyGro 9 minutos hace
PFS is not the ONLY acceptable endpoints for FDA acceptance -- they have list FIVE and PFS is one. Dr. Liau chose PFS as the primary endpoint for the SPORE UCLA. She also chose it for DCVax-L's P3 primary endpoint protocol too.
NWBO
SkeBallLarry SkeBallLarry 10 minutos hace
Comcast Drops Bombshell on MSNBC – Greenlights $7 Billion Spinoff of Cable Channels >

https://pjnewsletter.com/msnbc-comcast-nbcuniversal-cable/
LTListener LTListener 10 minutos hace
I am guessing the reference is to a larger funding package..
RSPI
SavetheOTC SavetheOTC 10 minutos hace
Do you have anything of value add or at least anything than bashing ecomike? What happened, you bought a stock based on his post that happened to be a lower? Investing in the OTC is a lot of losers with, hopefully, some big hits along the way.
NFTM

Su Consulta Reciente

Delayed Upgrade Clock